Alpha 2.0
Login Register
» Articles » PMID: 6976846

Clinical Problems Associated with the Use of Primaquine As a Tissue Schizontocidal and Gametocytocidal Drug

Overview
Journal Bull World Health Organ
Specialty Public Health
Date 1981 Jan 1
PMID 6976846
Citations 41
Authors
D F CLYDE
Affiliations
Soon will be listed here.
Abstract

Clinically important side-effects of primaquine are reviewed. These include gastrointestinal disturbances, methaemoglobinaemia, acute intravascular haemolysis in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD), and possibly immunosuppression through inhibition of lymphocyte proliferation. Dosages of 30 or 45 mg (base) of primaquine, given at weekly intervals, are suitable for patients with G6PD deficiency. If possible, primaquine should not be administered until the acute symptoms of the malaria attack have been brought under control.

Citing Articles

Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs.

Dembele L, Diakite O, Sogore F, Kedir S, Tandina F, Maiga M BMC Infect Dis. 2023; 23(1):405.

PMID: 37312065 PMC: 10265784. DOI: 10.1186/s12879-023-08381-y.

Comparative metabolism and tolerability of racemic primaquine and its enantiomers in human volunteers during 7-day administration.

Khan W, Wang Y, Chaurasiya N, Nanayakkara N, Bandara Herath H, Harrison K Front Pharmacol. 2023; 13:1104735.

PMID: 36726785 PMC: 9885159. DOI: 10.3389/fphar.2022.1104735.

A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania.

Mwaiswelo R, Ngasala B, Msolo D, Kweka E, Mmbando B, Martensson A Malar J. 2022; 21(1):84.

PMID: 35279143 PMC: 8917764. DOI: 10.1186/s12936-022-04100-1.

Is it time for Africa to adopt primaquine in the era of malaria control and elimination?.

Mwaiswelo R, Kabuga H, Kweka E, Baraka V Trop Med Health. 2022; 50(1):17.

PMID: 35216617 PMC: 8874101. DOI: 10.1186/s41182-022-00408-5.

Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.

Taylor W, Kheng S, Muth S, Tor P, Kim S, Bjorge S J Infect Dis. 2019; 220(11):1750-1760.

PMID: 31549159 PMC: 6804333. DOI: 10.1093/infdis/jiz313.

References
1.
. Primaquine induced haemolysis in G-6-PD deficient Burmese. Trans R Soc Trop Med Hyg. 1970; 64(5):785-6. DOI: 10.1016/0035-9203(70)90023-4. View
2.
Sietsma A, Naughton M, HARLEY J . Methaemoglobin levels in soldiers receiving antimalarial drugs. Med J Aust. 1971; 1(9):473-5. DOI: 10.5694/j.1326-5377.1971.tb87663.x. View
3.
CLYDE D, MCCARTHY V . Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg. 1977; 26(3):562-3. DOI: 10.4269/ajtmh.1977.26.562. View
4.
Roy R, Chakrapani K, Dhinagaran D, SITARAMAN N, Ghosh R . Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu. Indian J Med Res. 1977; 65(5):652-6. View
5.
Trenholme G, Carson P . Therapy and prophylaxis of malaria. JAMA. 1978; 240(21):2293-5. View